Functional Outcomes
Conditions
Keywords
PANSS, PSP, predictive validity, schizophrenia
Brief summary
The Positive and Negative Syndrome Scale (PANSS) is a widely used instrument for assessing symptom severity in schizophrenia, whereas the Personal and Social Performance Scale (PSP) provides a practical measure of functional outcomes. This study aimed to evaluate the predictive validity of the PSP for PANSS outcomes in individuals with schizophrenia. A total of 763 patients diagnosed with schizophrenia and receiving paliperidone treatment were recruited in a 12-week multicenter prospective study. Among participants with a baseline PANSS score greater than 90, those with a 12-week PSP score above 60 were more likely to achieve a reduction of more than 20% in PANSS scores, whereas those with a PSP score below 60 showed less improvement.
Detailed description
This study employed a 12-week, multicenter, prospective research design focusing on the administration of the antipsychotic medication paliperidone. Assessments were conducted at baseline, week 4, and week 12. Two widely used scales-the PANSS and PSP-were utilized to evaluate patients before and after treatment, followed by a correlation analysis of the results.
Interventions
DRUGThis study employed a 12-week, multicenter, prospective research design focusing on the administration of the antipsychotic medication paliperidone.
Assessments were conducted at baseline, week 4, and week 12. Two widely used scales-the PANSS and PSP-were utilized to evaluate patients before and after treatment, followed by a correlation analysis of the results.
Sponsors
Calo Psychiatric Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study employed a 12-week, multicenter, prospective research design focusing on the administration of the antipsychotic medication paliperidone. Assessments were conducted at baseline, week 4, and week 12. Two widely used scales-the PANSS and PSP-were utilized to evaluate patients before and after treatment, followed by a correlation analysis of the results.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* criteria diagnosis of schizophrenia
Exclusion criteria
* schizoaffective disorder * severe major depressive disorder * bipolar disorder * substance use disorders * organic brain conditions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the gender different in the effect of paliperidone treatment in schizophrenia | The differences were evaluated before treatment, and week 4 and week 12 after treatment. | The difference of paliperidone treatment between males and females were explored at baseline, week 4, and week 12. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The PANSS responses in schizophrenia with paliperidone | The responses of PANSS were evaluated before the treatment, and week 4 and week 12 after treatment | The Positive and Negative Syndrome Scale (PANSS) was utilized to evaluate the symptom improvment in individuals undergoing antipsychotic treatment. PANSS scores below 58 indicatemild symptoms, higher scores indicate more severe symptoms. |
Countries
Taiwan
Outcome results
None listed